Teleflex Hits New 52-Week High: What's Driving The Rally?
Zacks Investment Research | Jan 01, 2020 09:40PM ET
Shares of Teleflex Incorporated (NYSE:TFX) reached a new 52-week high of $376.54 on Dec 31, closing the session marginally lower at $376.44. The stock has rallied 8.5% since its third-quarter earnings announcement on Oct 31.
The company’s strong third-quarter earnings results, backed by robust segmental and global revenue growth, prompted the rally.
Let us delve deeper.
Q3 Performance
Teleflex exited the third quarter on a strong note, with better-than-expected earnings and revenue numbers. It witnessed year-over-year improvements in revenues in all of its segments as well as across Europe, Middle East and Africa (EMEA). It witnessed robust growth in Asia, OEM and Americas as well.
Teleflex is upbeat about continuing the recent trend in the EMEA and the Asia Pacific, backed by robust improvement in revenues on balanced growth across the majority of segments and all geographies. The continued UroLift momentum in the third quarter is impressive. The expansion of gross margin also buoys optimism. A raised revenue guidance, on a constant-currency basis, is an added positive.
Other Growth Drivers
Inclusion of NeoTract: Of late, Teleflex is upbeat about the robust performance of NeoTract, its acquired business. In the third quarter, the Interventional Urology business witnessed impressive growth on NeoTract’s continued strong momentum. Investors are also optimistic about the continued market adoption of the FDA-approved UroLift System. Teleflex is also working toward a limited launch of UroLift in mid to late 2020 in Japan, after it received the Shonin approval.
Vascular Solution Synergy: Investors are optimistic about accelerating growth of the company’s vascular and interventional access product portfolios. Vascular Solutions, acquired in February 2017, has been instrumental in expanding Teleflex’s outreach in the coronary and peripheral vascular market. It has also been generating increased cross-portfolio selling opportunities for the company.
Business in Asia: Investors are upbeat about Teleflex’s increasing focus on its expansion in geographies like Asia, which has been significantly contributing to the company’s top line. Notably, the company’s expansion in China is worth mentioning in this context. In the third quarter, its Asia unit reported year-over-year growth on strong rollout of its Vascular and Surgical products.
Get The News You Want
Zacks Rank & Key Picks
Currently, Teleflex carries a Zacks Rank #3 (Hold).
Some better-ranked stocks from the broader medical space are Haemonetics Corporation (NYSE:HAE) , National Vision Holdings, Inc (NASDAQ:EYE) and Medtronic plc (NYSE:MDT) .
Haemonetics currently flaunts a Zacks Rank #1 (Strong Buy) and has a projected long-term earnings growth rate of 13.5%. You can see Original post
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.